Recently, DP Technology announced the completion of a new round of financing exceeding 700 million RMB. The investors include Shanghai Zhongyuan Capital Management Co., Ltd., Magic Stone Alternative Investment, Loyal Valley Capital, Evergreen Scitech Delta, and several industrial capital firms. The funds from this round of financing will be mainly used to continue attracting top talents in the industry, deepen the full-stack capabilities from original algorithm innovation to industrial software and industry solutions, and strengthen the industrial application and commercial promotion of related technologies in scenarios such as biomedicine, new energy, chemical industry, and semiconductors.
DP Technology is committed to applying the "AI for Science" new research paradigm to build a new generation of multi-scale simulation and industrial infrastructure for the most fundamental biomedical, energy, materials, and information science and engineering research of human civilization. In recent years, DP Technology has focused on using artificial intelligence and molecular simulation algorithms, combined with advanced computing methods, to solve critical scientific problems, aiming to create a new generation of micro-scale industrial design and simulation platform for the most fundamental biomedical, energy, materials, and information science and engineering research of human civilization. By developing industrial design and simulation infrastructures such as the Bohrium® Research Cloud Platform, Hermite® Drug Computational Design Platform, Ridymo® Difficult Drug Target R&D Platform, and Piloteye™ Battery Design Automation Platform, DP Technology has also launched corresponding industry solutions.
Sun Weijie, founder and CEO of DP Technology, stated: "The world is essentially composed of atoms, and all human creations in the material world fundamentally involve the manipulation and combination of over 100 types of atoms. Now, in the era of AI for Science, the experience and principles behind these manipulations and combinations can be effectively captured in models and software. DP Technology aims to build hands, eyes, and brains for researchers to explore and manipulate the micro and mesoscopic worlds based on the new paradigm of AI for Science. This will transform research and development in fields such as drugs and batteries from large-scale experimental trial-and-error to a new paradigm of 'computational design-experimental validation,' providing various industries with effective software tools and solutions to drive technological progress, industrial upgrading, and the strengthening of China through science and technology."
MSA Capital stated: DP Technology is building a new generation of scientific research infrastructure, liberating the development process that was previously restricted by computational power, and providing entirely new possibilities for fields such as drug discovery and material exploration. The team possesses world-leading scientific research and technical capabilities and is a pioneer and leader in the AI for Science field globally. As a private equity investment firm deeply rooted in China with a global perspective, MSA Capital is delighted to discover such a young and highly innovative local team. This kind of infrastructure and innovation in fundamental logic is exactly what we have been seeking in the core technology sector.
Loyal Valley Capital stated: DP Technology is a pioneer in AI4S and the first team in China to achieve world-class original results in the AI4S field. We believe that AI technology will bring new tools to scientific research, promoting a shift from the "small workshop" model to a "platform-based research" model. Moreover, AI4S can help establish an effective system driven by industrial needs, leading to a transformation in research paradigms and new industry models. The integration of AI and industry will drive fundamental scientific research, using bottom-up innovation to propel industry development, delivering greater practical value across verticals like materials and pharmaceuticals. Most importantly, DP Technology has demonstrated strong product implementation and commercialization capabilities. Its developed research platforms and industrial software have gained recognition from many universities and industry clients, while its ability to engage in dialogue with leading companies and co-develop projects has been validated.